Short answer
SOLENO THERAPEUTICS INC (SLNO) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $95M with net income of $31M.
Q1 2026 key financials · XBRL
- Revenue
- $95M
- Net income
- $31M
- +171.7% YoY
- Operating margin
- 33.1%
- EPS (diluted)
- $0.59
- +162.1% YoY
Source: XBRL data from the SOLENO THERAPEUTICS INC (SLNO) Q1 2026 10-Q on SEC EDGAR. USD.
SOLENO THERAPEUTICS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $94.6M, up from $0 versus Q1 2025, driven by VYKAT XR sales
- Gross margin 98.7%, with cost of goods sold $1.2M
- Operating margin 33.1% versus (loss) margin in Q1 2025; net income $31.4M versus net loss $43.8M
- Cash $133.0M, marketable securities $396.0M, operating cash flow $26.0M versus use of $32.8M
- Outlook: continued VYKAT XR commercialization, with SG&A anticipated to increase; liquidity sufficient for next twelve months
Risk Factors
- Newly added merger risk: Neurocrine tender offer commenced April 20, 2026 at $53.00 per share
- Most material update: Offer delay or failure could reduce stock price, disrupt operations, and trigger a termination fee
- Regulatory risk: Voluntary withdrawal of VIOKAT EU marketing application on April 7, 2026 delayed commercialization plans
- Operational risk: Merger-related uncertainty may divert management attention and impair employee retention
- Financial risk: Merger costs, including professional services, insurance, and legal proceedings, may materially affect financial condition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SOLENO THERAPEUTICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.